Memo Therapeutics AG (“MTx”) is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer.
Products, services, technology
MTx's lead program, potravitug, is planned to start Phase III clinical development in 2026, targeting BK polyomavirus (BKPyV) infection in kidney transplant recipients and has the potential to become a first-in-class BKPyV disease-modifying therapy for kidney transplant patients.
Cooperation possibilities
MTx is focused on discovering novel oncology targets using our proprietary DROPZYLLA® discovery platform is a powerful antibody repertoire copying engine, both alone and in partnership.
- http://www.memo-therapeutics.com
- +41 44 515 91 40
- Send an email
Some insights
BKPyV infections double the risk of kidney loss and triple the risk of patient death in kidney transplant recipients. With no specific antiviral therapies for BKPyV available, MTx's potravitug is being evaluated in the largest placebo controlled clinical trial for treatment of BKPyV ever conducted.
Our core values are integral to what we do and we believe that adhering to them will be critical to our success. Driven by scientific innovation, we deliver high-quality results, fostered through a collaborative mindset, to make a difference for patients with viral infections and cancer.
Memo Therapeutics AG is proud to be a part of Switzerland's thriving biotech industry. The Swiss biotech ecosystem plays a key role in driving global healthcare innovation and we are open to partnering our proprietary DROPZYLLA® discovery platform to identify novel immunogenic antigens.
